StockData
Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc. (DCOY) stock

DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.95+0.05 (+5.37%)

Close on Nov 17, 2026Market cap $622.03KP/E –Yield –

Decoy Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Decoy Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.32M. For fiscal 2025 it was -$4.83M. The highest annual figure on record is $4.18M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.83M–
FY2024Dec 31, 2024-$4.53M–
FY2023Dec 31, 2023-$12.85M–
FY2022Dec 31, 2022-$17.60M–
FY2021Dec 31, 2021-$10.20M–
FY2020Dec 31, 2020-$10.31M–
FY2019Dec 31, 2019-$11.58M-377.2%
FY2018Dec 31, 2018$4.18M–
FY2017Dec 31, 2017-$27.72M–
FY2016Dec 31, 2016-$32.05M–
FY2015Dec 31, 2015-$20.75M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.65M–
Q1 FY2026Mar 31, 2026-$2.89M–
Q4 FY2025Dec 31, 2025-$1.14M–
Q3 FY2025Sep 30, 2025-$1.65M–
Q2 FY2025Jun 30, 2025-$862.30K–
Q1 FY2025Mar 31, 2025-$1.18M–
Q4 FY2024Dec 31, 2024-$742.52K–
Q3 FY2024Sep 30, 2024-$1.36M–
Q2 FY2024Jun 30, 2024-$1.07M–
Q1 FY2024Mar 31, 2024-$1.35M–
Q4 FY2023Dec 31, 2023-$1.51M–
Q3 FY2023Sep 30, 2023-$3.75M–
Q2 FY2023Jun 30, 2023-$4.42M–
Q1 FY2023Mar 31, 2023-$3.17M–
Q4 FY2022Dec 31, 2022-$4.71M–
Q3 FY2022Sep 30, 2022-$5.74M–
Q2 FY2022Jun 30, 2022-$3.62M–
Q1 FY2022Mar 31, 2022-$3.52M–
Q4 FY2021Dec 31, 2021-$2.72M–
Q3 FY2021Sep 30, 2021-$1.58M–
Q2 FY2021Jun 30, 2021-$3.17M–
Q1 FY2021Mar 31, 2021-$2.72M–
Q4 FY2020Dec 31, 2020-$1.37M–
Q3 FY2020Sep 30, 2020-$2.75M–
Q2 FY2020Jun 30, 2020-$2.48M–
Q1 FY2020Mar 31, 2020-$3.71M–
Q4 FY2019Dec 31, 2019-$2.64M-780.3%
Q3 FY2019Sep 30, 2019-$5.54M-125.8%
Q2 FY2019Jun 30, 2019-$1.53M–
Q1 FY2019Mar 31, 2019-$1.87M–
Q4 FY2018Dec 31, 2018$387.54K–
Q3 FY2018Sep 30, 2018$21.46M–
Q2 FY2018Jun 30, 2018-$8.26M–
Q1 FY2018Mar 31, 2018-$9.41M–
Q4 FY2017Dec 31, 2017-$5.76M–
Q3 FY2017Sep 30, 2017-$8.05M–
Q2 FY2017Jun 30, 2017-$5.69M–
Q1 FY2017Mar 31, 2017-$8.23M–
Q4 FY2016Dec 31, 2016-$6.30M–
Q3 FY2016Sep 30, 2016-$7.25M–

More Decoy Therapeutics figures

See a number that looks wrong?